Recent Advances in miRNA-Based Therapy for MASLD/MASH and MASH-Associated HCC
International Journal of Molecular Sciences · 14.11.2024 · 25 (22) · 12229
DOI: 10.3390/ijms252212229 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 14.11.2024. Verfasst von Sara Carpi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, University 'Magna Græcia' of Catanzaro, 88100 Catanzaro, Italy. Hauptthemen laut MEDLINE: MicroRNAs, Carcinoma, Hepatocellular, Liver Neoplasms, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Pisa.
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a growing health concern worldwide, affecting more than 1 billion adults. It may progress to metabolic dysfunction-associated steatohepatitis (MASH), cirrhosis, and ultimately hepatocellular carcinoma (HCC). Emerging evidence has demonstrated the role in this transition of microRNAs (miRNAs), which regulate the expression of genes associated with lipid metabolism, inflammation, fibrosis, and cell proliferation. Specific miRNAs have been identified to exacerbate or mitigate fibrotic and carcinogenic processes in hepatic cells. The modulation of these miRNAs through synthetic mimics or inhibitors represents a promising therapeutic strategy. Preclinical models have demonstrated that miRNA-based therapies can attenuate liver inflammation, reduce fibrosis, and inhibit tumorigenesis, thus delaying or preventing the onset of HCC. However, challenges such as delivery mechanisms, off-target effects, and long-term safety remain to be addressed. This review, focusing on recently published preclinical and clinical studies, explores the pharmacological potential of miRNA-based interventions to prevent MASLD/MASH and progression toward HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Sciences, University 'Magna Græcia' of Catanzaro, 88100 Catanzaro, Italy.
- NEST (National Enterprise for nanoScience and nanoTechnology), Istituto Nanoscienze-CNR and Scuola Normale Superiore, 41125 Modena, Italy.
- Department of Pharmacy, University of Pisa, 56126 Pisa, Italy.
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35131 Padova, Italy.
ORCID-Profile: Simona Daniele, Daniela Gabbia
Förderung
- University of Pisa
Zitieren
APA
Carpi, S., Daniele, S., de Almeida, J. F. M., & Gabbia, D. (2024). Recent Advances in miRNA-Based Therapy for MASLD/MASH and MASH-Associated HCC. International Journal of Molecular Sciences, 25(22), 12229. https://doi.org/10.3390/ijms252212229
Vancouver
Carpi S, Daniele S, de Almeida JFM, Gabbia D. Recent Advances in miRNA-Based Therapy for MASLD/MASH and MASH-Associated HCC. International Journal of Molecular Sciences. 2024;25(22):12229. doi:10.3390/ijms252212229
BibTeX
@article{Carpi2024,
author = {Carpi, Sara and Daniele, Simona and de Almeida, Jacqueline Fátima Martins and Gabbia, Daniela},
title = {Recent Advances in miRNA-Based Therapy for MASLD/MASH and MASH-Associated HCC},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {22},
pages = {12229},
doi = {10.3390/ijms252212229}
}
EUVIMED